Treatment with Ivermectin Is Associated with Decreased Mortality in COVID-19 Patients: Analysis of a National Federated Database
et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2021.12.096
, Treatment with Ivermectin Is Associated with Decreased Mortality in COVID-19 Patients: Analysis of a National.., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2021.12.096
PSM retrospective 41,608 patients in the USA, 1,072 treated with ivermectin and 40,536 treated with remdesivir, showing lower mortality with ivermectin treatment.This study was presented at a conference (IMED 2021). Submissions were peer-reviewed. The treatment/control group sizes align with the estimated percentage of hospitals that used ivermectin vs. remdesivir. Hospitals in the USA receive financial incentives to use remdesivir.Authors have self-censored the conference report of this result, not due to any error in the analysis, but because they believe ivermectin "has proven to be ineffective in clinical trials". This is incorrect, while some studies show no statistically significant effect, 59 studies show statistically significant positive results for one or more outcomes (33 prospective and 26 retrospective studies, including 23 RCTs) [Abbas, Ahmed, Ahsan, Alam, Aref, Aref (B), Babalola, Behera, Behera (B), Bernigaud, Biber, Borody, Budhiraja, Bukhari, Cadegiani, Carvallo, Carvallo (B), Chaccour, Chahla, Chahla (B), Chowdhury, de Jesús Ascencio-Montiel, de la Rocha, Desort-Henin, Efimenko, Elalfy, Espitia-Hernandez, Faisal, Ghauri, Gorial, Hashim, Hellwig, IVERCOR PREP, Kerr, Khan, Lim, Lima-Morales, Mahmud, Mayer, Merino, Mondal, Morgenstern, Mourya, Naggie, Okumuş, Ozer, Qadeer, Rajter, Rezai, Rezk, Samajdar, Seet, Shahbaznejad, Shimizu, Shouman, Soto-Becerra, Spoorthi, Tanioka, Thairu].The self-censorship and decision not to submit to a journal provide further evidence of a negative publication bias for ivermectin research.This is the 80th of 97 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001 (1 in 2 sextillion). 46 studies are RCTs, which show efficacy with p=0.00000014.
1.
Abbas et al., Indian Journal of Pharmaceutical Sciences, doi:10.36468/pharmaceutical-sciences.spl.416,
The Effect of Ivermectin on Reducing Viral Symptoms in Patients with Mild COVID-19,
https://www.ijpsonline.com/abstrac..tients-with-mild-covid19-4455.html.
2.
Ahmed et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.11.191,
A five day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness,
https://www.sciencedirect.com/science/article/pii/S1201971220325066.
3.
Ahsan et al., Cureus, doi:10.7759/cureus.14761 ,
Clinical Variants, Characteristics, and Outcomes Among COVID-19 Patients: A Case Series Analysis at a Tertiary Care Hospital in Karachi, Pakistan,
https://www.cureus.com/articles/56..-care-hospital-in-karachi-pakistan.
4.
Alam et al., European Journal ofMedical and Health Sciences, doi:10.24018/ejmed.2020.2.6.599,
Ivermectin as Pre-exposure Prophylaxis for COVID-19 among Healthcare Providers in a Selected Tertiary Hospital in Dhaka – An Observational Study,
https://ejmed.org/index.php/ejmed/article/view/599.
5.
Aref et al., International Journal of Nanomedicine, doi:10.2147/IJN.S313093 ,
Clinical, Biochemical and Molecular Evaluations of Ivermectin Mucoadhesive Nanosuspension Nasal Spray in Reducing Upper Respiratory Symptoms of Mild COVID-19,
https://www.dovepress.com/clinical..peer-reviewed-fulltext-article-IJN.
6.
Aref (B) et al., Infection and Drug Resistance, doi:10.2147/IDR.S381715,
Possible Role of Ivermectin Mucoadhesive Nanosuspension Nasal Spray in Recovery of Post-COVID-19 Anosmia,
https://www.dovepress.com/possible..peer-reviewed-fulltext-article-IDR.
7.
Babalola et al., QJM: An International Journal of Medicine, doi:10.1093/qjmed/hcab035 (preprint 1/6),
Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in Lagos,
https://academic.oup.com/qjmed/adv../doi/10.1093/qjmed/hcab035/6143037.
8.
Behera et al., PLoS ONE, doi:10.1371/journal.pone.0247163 (preprint 11/3),
Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: A matched case-control study,
https://journals.plos.org/plosone/..le?id=10.1371/journal.pone.0247163.
9.
Behera (B) et al., Cureus 13:8, doi:10.7759/cureus.16897 (preprint 2/15/21),
Prophylactic Role of Ivermectin in Severe Acute Respiratory Syndrome Coronavirus 2 Infection Among Healthcare Workers,
https://www.cureus.com/articles/64..infection-among-healthcare-workers.
10.
Bernigaud et al., Annals of Dermatology and Venereology, doi:10.1016/j.annder.2020.09.231,
Ivermectin benefit: from scabies to COVID-19, an example of serendipity,
https://www.sciencedirect.com/science/article/pii/S015196382030627X.
11.
Biber et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2022.07.003 (results 2/12/21),
The effect of ivermectin on the viral load and culture viability in early treatment of non-hospitalized patients with mild COVID-19 – A double-blind, randomized placebo-controlled trial,
https://www.sciencedirect.com/science/article/pii/S120197122200399X.
12.
Borody et al., TrialSite News,
Combination Therapy For COVID-19 Based on Ivermectin in an Australian Population,
https://covidmedicalnetwork.com/me..lSite-media-release-19.10.2021.pdf.
13.
Budhiraja et al., medRxiv, doi:10.1101/2020.11.16.20232223,
Clinical Profile of First 1000 COVID-19 Cases Admitted at Tertiary Care Hospitals and the Correlates of their Mortality: An Indian Experience,
https://www.medrxiv.org/content/10.1101/2020.11.16.20232223v1.
14.
Bukhari et al., medRxiv, doi:10.1101/2021.02.02.21250840 (results 1/16),
Efficacy of Ivermectin in COVID-19 Patients with Mild to Moderate Disease,
https://www.medrxiv.org/content/10.1101/2021.02.02.21250840v1.
15.
Cadegiani et al., New Microbes and New Infections, doi:10.1016/j.nmni.2021.100915 (preprint 11/4/2020),
Early COVID-19 Therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in Outpatient Settings Significantly Improved COVID-19 outcomes compared to Known outcomes in untreated patients,
https://www.sciencedirect.com/science/article/pii/S2052297521000792.
16.
Carvallo et al., NCT04425850,
Usefulness of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19 (IVERCAR),
https://clinicaltrials.gov/ct2/show/results/NCT04425850.
17.
Carvallo (B) et al., Journal of Biomedical Research and Clinical Investigation, doi:10.31546/2633-8653.1007,
Study of the Efficacy and Safety of Topical Ivermectin + Iota-Carrageenan in the Prophylaxis against COVID-19 in Health Personnel,
https://medicalpressopenaccess.com/upload/1605709669_1007.pdf.
18.
Chaccour et al., EClinicalMedicine, doi:10.1016/j.eclinm.2020.100720 (preprint 12/7),
The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial,
https://www.thelancet.com/journals../PIIS2589-5370(20)30464-8/fulltext.
19.
Chahla et al., Research, Society and Development, doi:10.33448/rsd-v11i8.30844 (preprint 3/30/2021),
Randomized trials - Ivermectin repurposing for COVID-19 treatment of outpatients with mild disease in primary health care centers,
https://rsdjournal.org/index.php/rsd/article/view/30844.
20.
Chahla (B) et al., American Journal of Therapeutics, doi:10.1097/MJT.0000000000001433,
Intensive Treatment With Ivermectin and Iota-Carrageenan as Pre-exposure Prophylaxis for COVID-19 in Health Care Workers From Tucuman, Argentina,
https://journals.lww.com/10.1097/MJT.0000000000001433.
21.
Chowdhury et al., Eurasian Journal of Medicine and Oncology, doi:10.14744/ejmo.2021.16263,
A Comparative Study on Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin Therapy on COVID-19 Patients,
https://ejmo.org/10.14744/ejmo.2021.16263/.
22.
de Jesús Ascencio-Montiel et al., Archives of Medical Research, doi:10.1016/j.arcmed.2022.01.002,
A Multimodal Strategy to Reduce the Risk of Hospitalization/death in Ambulatory Patients with COVID-19,
https://www.sciencedirect.com/science/article/pii/S0188440922000029.
23.
de la Rocha et al., BMC Infectious Diseases, doi:10.1186/s12879-022-07890-6 (preprint 5/23/2022),
Ivermectin compared with placebo in the clinical course in Mexican patients with asymptomatic and mild COVID-19: a randomized clinical trial,
https://bmcinfectdis.biomedcentral..rticles/10.1186/s12879-022-07890-6.
24.
Desort-Henin et al., ECCMID 2023 (results released 1/5/2023),
The SAIVE Trial, Post-Exposure use of ivermectin in Covid-19 prevention: Efficacy and Safety Results,
https://www.medincell.com/wp-conte../04/Poster-SAIVE-April2023-OK3.pdf.
25.
Efimenko et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2021.12.096,
Treatment with Ivermectin Is Associated with Decreased Mortality in COVID-19 Patients: Analysis of a National Federated Database,
https://www.sciencedirect.com/science/article/pii/S1201971221009887.
26.
Elalfy et al., J. Med. Virol., doi:10.1002/jmv.26880,
Effect of a combination of Nitazoxanide, Ribavirin and Ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID-1,
https://onlinelibrary.wiley.com/doi/10.1002/jmv.26880.
27.
Espitia-Hernandez et al., Biomedical Research, 31:5,
Effects of Ivermectin-azithromycin-cholecalciferol combined therapy on COVID-19 infected patients: A proof of concept study,
https://www.biomedres.info/biomedi..-proof-of-concept-study-14435.html.
28.
Faisal et al., The Professional Medical Journal, doi:10.29309/TPMJ/2021.28.05.5867,
Potential use of azithromycin alone and in combination with ivermectin in fighting against the symptoms of COVID-19,
http://theprofesional.com/index.php/tpmj/article/view/5867.
29.
Ghauri et al., International Journal of Clinical Studies & Medical Case Reports, doi:10.46998/IJCMCR.2021.13.000320 (preprint 12/15/2020),
Ivermectin Use Associated with Reduced Duration of Covid-19 Febrile Illness in a Community Setting,
https://ijclinmedcasereports.com/pdf/IJCMCR-RA-00320.pdf.
30.
Gorial et al., medRxiv, doi:10.1101/2020.07.07.20145979,
Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial),
https://www.medrxiv.org/content/10.1101/2020.07.07.20145979v1.
31.
Hashim et al., Iraqi Journal of Medical Science, 19:1,
Controlled randomized clinical trial on using Ivermectin with doxycycline for treating COVID-19 patients in Baghdad, Iraq,
http://www.iraqijms.net/upload/pdf/iraqijms60db8b76d3b1e.pdf.
32.
Hellwig et al., International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.106248,
A COVID-19 Prophylaxis? Lower incidence associated with prophylactic administration of Ivermectin,
https://www.sciencedirect.com/science/article/pii/S0924857920304684.
33.
IVERCOR PREP, Preliminary Results,
Ivermectina en agentes de salud e IVERCOR COVID19,
https://web.archive.org/web/202102..Crusher/status/1365420061859717124.
34.
Kerr et al., Cureus, doi:10.7759/cureus.21272 (preprint 12/11/2021),
Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching,
https://www.cureus.com/articles/82..ts-using-propensity-score-matching.
35.
Khan et al., Archivos de Bronconeumología, doi:10.1016/j.arbres.2020.08.007,
Ivermectin treatment may improve the prognosis of patients with COVID-19,
https://www.archbronconeumol.org/e..ognosis-articulo-S030028962030288X.
36.
Lim et al., JAMA, doi:10.1001/jamainternmed.2022.0189 (data 11/3/21),
Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities: The I-TECH Randomized Clinical Trial,
https://jamanetwork.com/journals/j..ternalmedicine/fullarticle/2789362.
37.
Lima-Morales,
Effectiveness of a multidrug therapy consisting of ivermectin, azithromycin, montelukast and acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico,
https://www.sciencedirect.com/science/article/pii/S1201971221001004.
38.
Mahmud et al., Journal of International Medical Research, doi:10.5061/dryad.qjq2bvqf6 (preprint 10/9/20),
Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial,
https://journals.sagepub.com/doi/10.1177/03000605211013550.
39.
Mayer et al., Frontiers in Public Health, doi:10.3389/fpubh.2022.813378 (preprint 9/23/2021),
Safety and Efficacy of a MEURI Program for the Use of High Dose Ivermectin in COVID-19 Patients,
https://www.frontiersin.org/articles/10.3389/fpubh.2022.813378/full.
40.
Merino et al., Preprint,
Ivermectin and the odds of hospitalization due to COVID-19: evidence from a quasi-experimental analysis based on a public intervention in Mexico City,
http://web.archive.org/web/2021121..9?action=download&direct&version=1.
41.
Mondal et al., Journal of the Indian Medical Association, 119:5,
Prevalence of COVID-19 Infection and Identification of Risk Factors among Asymptomatic Healthcare Workers: A Serosurvey Involving Multiple Hospitals in West Bengal,
https://onlinejima.com/read_journals.php?article=683.
42.
Morgenstern et al., Cureus, doi:10.7759/cureus.17455 (preprint 4/16/2021),
Ivermectin as a SARS-CoV-2 Pre-Exposure Prophylaxis Method in Healthcare Workers: A Propensity Score-Matched Retrospective Cohort Study,
https://www.cureus.com/articles/63..matched-retrospective-cohort-study.
43.
Mourya et al., Int. J. Health and Clinical Research,
Comparative Analytical Study of Two Different Drug Regimens in Treatment of Covid 19 Positive Patients in Index Medical College Hospital and Research Center, Indore, India,
https://ijhcr.com/index.php/ijhcr/article/view/1263.
44.
Naggie et al., JAMA, doi:10.1001/jama.2022.18590,
Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial,
https://jamanetwork.com/journals/jama/fullarticle/2797483.
45.
Okumuş et al., BMC Infectious Diseases, doi:10.1186/s12879-021-06104-9 (preprint 1/12),
Evaluation of the Effectiveness and Safety of Adding Ivermectin to Treatment in Severe COVID-19 Patients,
https://bmcinfectdis.biomedcentral..rticles/10.1186/s12879-021-06104-9.
46.
Ozer et al., Journal of Medical Virology, doi:10.1002/jmv.27469,
Effectiveness and Safety of Ivermectin in COVID-19 Patients: A Prospective Study at A Safety-Net Hospital,
https://onlinelibrary.wiley.com/doi/10.1002/jmv.27469.
47.
Qadeer et al., Pakistan Journal of Medical and Health Sciences, doi:10.53350/pjmhs2216824,
Ivermectin A Potential Treatment In Covid-19, Related to Critical Illness,
https://pjmhsonline.com/index.php/pjmhs/article/view/2153.
48.
Rajter et al., Chest, doi:10.1016/j.chest.2020.10.009,
Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID-19 (ICON study),
https://www.sciencedirect.com/science/article/pii/S0012369220348984.
49.
Rezai et al., Frontiers in Medicine, doi:10.3389/fmed.2022.919708,
Non-effectiveness of Ivermectin on Inpatients and Outpatients With COVID-19; Results of Two Randomized, Double-Blinded, Placebo-Controlled Clinical Trials,
https://www.frontiersin.org/articles/10.3389/fmed.2022.919708/full.
50.
Rezk et al., Zagazig University Medical Journal, doi:10.21608/zumj.2021.92746.2329,
miRNA-223-3p, miRNA- 2909 and Cytokines Expression in COVID-19 Patients Treated with Ivermectin,
https://journals.ekb.eg/article_202150_0.html.
51.
Samajdar et al., Journal of the Association of Physicians India, 69:11,
Ivermectin and Hydroxychloroquine for Chemo-Prophylaxis of COVID-19: A Questionnaire Survey of Perception and Prescribing Practice of Physicians vis-a-vis Outcomes,
https://japi.org/x2a464b4/ivermect..ice-of-physicians-vis-vis-outcomes.
52.
Seet et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2021.04.035,
Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: an open-label randomized trial,
https://www.ijidonline.com/article/S1201-9712(21)00345-3/fulltext.
53.
Shahbaznejad et al., Clinical Therapeutics, doi:10.1016/j.clinthera.2021.04.007 (partial results available 1/19),
Effects of Ivermectin in Patients With COVID-19: A Multicenter, Double-blind, Randomized, Controlled Clinical Trial,
https://www.sciencedirect.com/scie../article/abs/pii/S0149291821002010.
54.
Shimizu et al., Journal of Infection and Chemotherapy, doi:10.1016/j.jiac.2021.12.024,
Ivermectin administration is associated with lower gastrointestinal complications and greater ventilator-free days in ventilated patients with COVID-19: A propensity score analysis,
https://www.jiac-j.com/article/S1341-321X(21)00360-3/fulltext.
55.
Shouman et al., Journal of Clinical and Diagnostic Research, doi:10.7860/JCDR/2020/46795.0000,
Use of Ivermectin as a Potential Chemoprophylaxis for COVID-19 in Egypt: A Randomised Clinical Trial,
https://www.jcdr.net/articles/PDF/..Sh)_PF1(SY_OM)_PFA_(OM)_PN(KM).pdf.
56.
Soto-Becerra et al., medRxiv, doi:10.1101/2020.10.06.20208066,
Real-World Effectiveness of hydroxychloroquine, azithromycin, and ivermectin among hospitalized COVID-19 patients: Results of a target trial emulation using observational data from a nationwide Healthcare System in Peru,
https://www.medrxiv.org/content/10.1101/2020.10.06.20208066v1.
57.
Spoorthi et al., IAIM, 2020, 7:10, 177-182,
Utility of Ivermectin and Doxycycline combination for the treatment of SARSCoV-2,
http://iaimjournal.com/wp-content/..oads/2020/10/iaim_2020_0710_23.pdf.
58.
Tanioka et al., medRxiv, doi:10.1101/2021.03.26.21254377,
Why COVID-19 is not so spread in Africa: How does Ivermectin affect it?,
https://www.medrxiv.org/content/10.1101/2021.03.26.21254377v1.
59.
Thairu et al., Journal of Pharmaceutical Research International, doi:10.9734/jpri/2022/v34i44A36328 (preprint 2/25/2022),
A Comparison of Ivermectin and Non Ivermectin Based Regimen for COVID-19 in Abuja: Effects on Virus Clearance, Days-to-discharge and Mortality,
https://journaljpri.com/index.php/JPRI/article/view/36328.
|
risk of death, 69.2% lower, OR 0.31, p < 0.001, treatment 1,072, control 40,536, propensity score matching, RR approximated with OR.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Efimenko et al., 28 Feb 2022, retrospective, propensity score matching, USA, peer-reviewed, 6 authors, study period 1 January, 2020 - 11 July, 2021, dosage not specified, this trial compares with another treatment - results may be better when compared to placebo.
Development of Duplex and Multiplex Reverse Transcription Loop Mediated Isothermal Amplification (RT-LAMP) Assays for Clinical Diagnosis of SARS-COV-2 in Sri Lanka
International Journal of Infectious Diseases, doi:10.1016/j.ijid.2021.12.095
Purpose: Despite the rollout of several vaccines targeting SARS-CoV-2, attainment of near-universal vaccination is a challenging task, particularly for low-and middle-income nations such as Sri Lanka. Rapid, reliable diagnostics for the detection of the virus is of vital importance for the predominantly export-and tourismbased economy of the country. Herein, we report the development of a RT-LAMP assay as an alternative to the gold-standard RT-qPCR method for diagnostic laboratories in Sri Lanka in a cost-effective and highly reliable manner. Methods & Materials: About 313 nasopharyngeal and oropharyngeal samples from the community were collected and subjected to RNA purification and subjected to simultaneous RT-qPCR and RT-LAMP experiments by using previously published primers in a thermocycler. Duplex (containing N and E gene primers) and multiplex (containing N, E and ORF1ab gene primers) RT-LAMP assay results were compared with standard RT-qPCR results using an agreement attribute statistical test. The effect of guanidine hydrochloride was also analyzed. Results: The limit of detection for the duplex assay was found to be 10 copies μL-1 at a constant temperature of 63 °C, and 5 copies μL-1 for multiplex assays at 66.4 °C. Both types of RT-LAMP assay were specific only for the SARS-COV-2 virus, successfully distinguishing it from multiple other human viruses. Attribute agreement analysis between duplex-and multiplex RT-LAMP vs RT-qPCR yielded 93% and 96.5% scores, respectively. Moreover, both RT-LAMP assays showed 100% agreement with RT-qPCR when Ct was < 25 in positive samples and showed 100% (duplex) or 97.22% (multiplex) at 35 ≥ Ct ≥25. The discrepancy between agreements at higher Ct values was attributed to the higher sensitivity of the multiplex RT-LAMP assay. The addition of guanidine hydrochloride increased the sensitivity and decreased detection time significantly for both the duplex and multiplex assays. Conclusion: Overall, we have demonstrated a potentially rapidly deployable diagnostic test kit not only for widespread community use but particularly for high-risk locations such as ports of entry or manufacturing facilities to mitigate the effects of the SARS-CoV-2 virus in Sri Lanka.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.